用户验证的应用
推荐稀释比例
- WB1/1000
- IP1/30
详细信息
背景信息
What is this antibody validated in? Anti-YTHDF2 antibody [EPR20318] (ab220163) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP) in Human, Mouse, Rat samples. What is the molecular weight of YTHDF2? Anti-YTHDF2 [EPR20318] (ab220163) specifically detects a band for YTHDF2 (UniProt: Q9Y5A9) at a molecular weight of 62kDa. Trusted by the scientific community Anti-YTHDF2 [EPR20318] (ab220163) was first used in a scientific publication in 2018 and has been cited over 50 times in peer-reviewed journals. Specificity confirmed The specificity of Anti-YTHDF2 antibody [EPR20318] (ab220163) has been confirmed by Western blot testing in YTHDF2 Knockout mESC cells. Other related products We have a range of other formats of antibody clone [EPR20318] also available for your convenience: ab220163, Carrier free - ab245129 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.
文献引用 (92)
BARD1-mediated stabilization of METTL14 promotes retinal neovascularization by m6A-modifying MXD1 mRNA on a YTHDF2-dependent manner.
BARD1介导的METTL14稳定化通过m6A修饰MXD1 mRNA,以YTHDF2依赖的方式促进视网膜新生血管形成
Targeting YTHDF2 with pH-responsive siRNA nanoparticles suppresses MYC m6A modification and restores antitumor immunity in hepatocellular carcinoma
利用pH响应性siRNA纳米颗粒靶向YTHDF2可抑制MYC m6A修饰并恢复肝细胞癌的抗肿瘤免疫力。
Enriched environment inhibits GLT-1 ubiquitination by downregulating SMURF1 to attenuate ischemic brain injury induced excitotoxicity.
富集环境通过下调 SMURF1 来抑制 GLT-1 泛素化,从而减轻缺血性脑损伤引起的兴奋性毒性
KCTD10 inhibits lung cancer metastasis and angiogenesis via ubiquitin-mediated β-catenin degradation.
KCTD10 通过泛素介导的β-catenin降解抑制肺癌转移和血管生成
Molecular mechanism of ZC3H13 -mediated ferroptosis in doxorubicin resistance of triple negative breast cancer
ZC3H13介导的铁死亡在三阴性乳腺癌阿霉素耐药中的分子机制
The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN.
RNA结合蛋白YTHDF3通过调节EZRIN影响胃癌细胞的迁移和对紫杉醇的反应
ZHX2 inhibits diabetes-induced liver injury and ferroptosis by epigenetic silence of YTHDF2
ZHX2 通过表观遗传沉默 YTHDF2 来抑制糖尿病引起的肝损伤和铁死亡
METTL3-mediated m(6)A modification promotes intervertebral disc degeneration.
METTL3 介导的 m(6)A 修饰促进椎间盘退变
WTAP Accelerates Exhaustion of CD8(+) T Cells and Progression of Hepatocellular Carcinoma by Promoting m6A Modification and Translation of PD1 mRNA.
WTAP 通过促进 PD1 mRNA 的 m6A 修饰和翻译,加速 CD8(+) T 细胞的耗竭和肝细胞癌的进展
YTHDF2 promotes the metastasis of oral squamous cell carcinoma through the JAK-STAT pathway.
YTHDF2 通过 JAK-STAT 通路促进口腔鳞状细胞癌的转移
- 1
- 2
- 3
- 4
- 5
- 6
- 10